Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

Prognostic and Clinicopathologic Associations ofBRAFMutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study

(2014) Jin-Woo Hong et al.   Annals of Dermatology

Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection

(2014) M. Picard et al.   BRITISH JOURNAL OF DERMATOLOGY

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

(2014) Miguel Melo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

(2014) Mingzhao Xing et al.   JOURNAL OF CLINICAL ONCOLOGY

TERTpromoter mutation is uncommon in acral lentiginous melanoma

(2014) Jau-Yu Liau et al.   JOURNAL OF CUTANEOUS PATHOLOGY

TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation

(2014) Helena Pópulo et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

(2014) Klaus G. Griewank et al.   JNCI-Journal of the National Cancer Institute

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

(2014) Diana Meckbach et al.   PLoS One

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

(2014) João Vinagre et al.   VIRCHOWS ARCHIV

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma

(2014) Barbara Heidenreich et al.   Nature Communications

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer

(2013) V Eklöf et al.   BRITISH JOURNAL OF CANCER

Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma

(2013) Xiaoli Liu et al.   CELL CYCLE

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

(2013) Xiaoli Liu et al.   ENDOCRINE-RELATED CANCER

Frequent SomaticTERTPromoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease

(2013) Iñigo Landa et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma

(2013) A Tallet et al.   ONCOGENE

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma

(2013) Klaus G. Griewank et al.   PLoS One

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT Promoter Mutations in Familial and Sporadic Melanoma

(2013) S. Horn et al.   SCIENCE

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

Frequency of TERT promoter mutations in human cancers

(2013) João Vinagre et al.   Nature Communications

Regulation of the human catalytic subunit of telomerase (hTERT)

(2012) Michael Daniel et al.   GENE

Molecular biology of melanoma

(2012) Julie M. Swick et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

Correlation between theBRAFV600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases

(2010) Fulvio Basolo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Targeted Therapy for Melanoma: A Primer

(2010) Michael A. Davies et al.   Surgical Oncology Clinics of North America

Phospho-ERK Staining Is a Poor Indicator of the Mutational Status of BRAF and NRAS in Human Melanoma

(2008) Roland Houben et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY